Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
11 hedge funds and large institutions have $1.89M invested in Evoke Pharma in 2016 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
37% more capital invested
Capital invested by funds: $1.38M → $1.89M (+$506K)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
21% less funds holding
Funds holding: 14 → 11 (-3)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.02K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$512 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARTA
A.R.T. Advisors
New York
|
-$82K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$12.8K |
| 3 |
Walleye Trading
New York
|
-$5K |
| 4 |
Millennium Management
New York
|
-$4.61K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OM
1
Opaleye Management
Boston,
Massachusetts
| $662K | – | – | – |
|
|
2
Millennium Management
New York
| $306K | -$4.61K | -9 | -2% |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $302K | +$1.02K | +2 | +0.5% |
|
|
KCM
4
Knoll Capital Management
Miami,
Florida
| $283K | – | – | – |
|
5
California Public Employees Retirement System
Sacramento,
California
| $187K | – | – | – |
|
6
Bank of New York Mellon
New York
| $118K | – | – | – |
|
7
Bank of America
Charlotte,
North Carolina
| $15K | – | – | – |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $5K | -$12.8K | -25 | -78% |
|
|
BFA
9
BlackRock Fund Advisors
San Francisco,
California
| $5K | +$512 | +1 | +20% |
|
|
BIM
10
BlackRock Investment Management
Wilmington,
Delaware
| $2K | – | – | – |
|
11
Geode Capital Management
Boston,
Massachusetts
| $80 | – | – | – |
|
|
ARTA
12
A.R.T. Advisors
New York
| – | -$82K | -173 | Closed |
|
|
13
Walleye Trading
New York
| – | -$5K | -10 | Closed |
|
|
14
UBS Group
Zurich,
Switzerland
| – | -$4K | -9 | Closed |
|
EVOK Hedge Fund Activity: Q1 2016 in Review
11 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q1 2016, worth a combined $1.89M — up 37% from $1.38M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of EVOK and 0 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Vanguard Group, adding an estimated $1.02K. The largest seller was A.R.T. Advisors, exiting entirely with an estimated $82K sold.
- 11 institutional investors held Evoke Pharma (EVOK) as of Q1 2016, down from 14 in Q4 2015.
- Funds reported $1.89M of Evoke Pharma stock for Q1 2016, up 37% quarter-over-quarter.
- 0 funds opened new Evoke Pharma positions in Q1 2016 and 3 closed out, a net change of -3 holders.
- The largest Evoke Pharma buyer in Q1 2016 was Vanguard Group, an estimated $1.02K added.
- The largest Evoke Pharma seller in Q1 2016 was A.R.T. Advisors, an estimated $82K sold.
Based on aggregated 13F filings for Q1 2016.